Abstract
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is an organ-threatening and life-threatening multi-system autoimmune disease in which B cell-derived ANCAs cause neutrophil activation and endothelial damage, strongly implicating these autoantibodies in the pathogenesis of AAV. B cell depletion with rituximab combined with glucocorticoids is associated with a reduction in ANCA concentrations and with clinical remission in the majority of patients with AAV. However, the safety profile of rituximab is no better than that of conventional therapy with cyclophosphamide, and long-term glucocorticoid treatment is needed to achieve and maintain disease-free remission. A need for new therapies exists to reduce the time to remission, to spare the use of glucocorticoids and to promote long-lasting remission without the risk of relapse. Over the past 20 years, there has been great interest in therapeutically targeting B cell cytokines, such as B cell-activating factor (BAFF), in many autoimmune disease settings. Dual B cell-targeted immunotherapy that combines B cell depletion and BAFF blockade could potentially be more efficacious than targeting either mechanism alone. In this Review, the theoretical background for use of this combination approach in AAV is presented and discussed.
Key points
-
B cell depletion therapy with rituximab is an effective alternative to cyclophosphamide for the induction of remission in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV).
-
The safety profile of rituximab is not better than that of conventional therapy, suggesting that new therapies are needed to treat patients with AAV.
-
B cell-activating factor (BAFF), an essential cytokine in B cell survival and development, is associated with autoimmune disease, being present at high concentrations in patients with AAV.
-
Autoreactive B cells can be rescued from deletion in the presence of high concentrations of BAFF.
-
BAFF antagonism with belimumab is efficacious in patients with systemic lupus erythematosus and is undergoing evaluation in several other autoimmune diseases, including AAV.
-
Combination therapy with rituximab and belimumab is an attractive therapeutic strategy, as additional BAFF antagonism might enable effective early B cell depletion and reduce the re-emergence of autoreactive B cells.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
02 November 2018
In the section ‘Combining B cell-targeted therapies’ in the originally published version of this article, the 24-week interim analysis for the CALIBRATE study was incorrectly given as the 2- to 4-week interim analysis. This error has now been corrected in the HTML and PDF versions of the manuscript.
References
Jennette, J. C. et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 65, 1–11 (2013).
Christiaan Hagen, E. et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis for the EC/BCR project for ANCA assay standardisation. Kidney Int. 53, 743–753 (1998).
Sablé-Fourtassou, R. et al. Antineutrophil cytoplasmic antibodies and the Churg–Strauss syndrome. Ann. Intern. Med. 143, 632–638 (2005).
Jennette, J. C. & Falk, R. J. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat. Rev. Rheumatol. 10, 463–473 (2014).
Voswinkel, J. et al. Single cell analysis of B lymphocytes from Wegener’s granulomatosis: B cell receptors display affinity maturation within the granulomatous lesions. Clin. Exp. Immunol. 154, 339–345 (2008).
Popa, E. R., Stegeman, C. A., Bos, N. A., Kallenberg, C. G. & Tervaert, J. W. Differential B- and T-cell activation in Wegener’s granulomatosis. J. Allergy Clin. Immunol. 103, 885–894 (1999).
Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221–232 (2010).
Hoffman, W., Lakkis, F. G. & Chalasani, G. B cells, antibodies, and more. Clin. J. Am. Soc. Nephrol. 11, 137–154 (2016).
Brouwer, E. et al. Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener’s granulomatosis and clinically related disorders. Clin. Exp. Immunol. 83, 379–386 (1991).
Abdulahad, W. H., van der Geld, Y. M., Stegeman, C. A. & Kallenberg, C. G. M. Persistent expansion of CD4+ effector memory T cells in Wegener’s granulomatosis. Kidney Int. 70, 938–947 (2006).
Morgan, M. D. et al. Patients with Wegener’s granulomatosis demonstrate a relative deficiency and functional impairment of T regulatory cells. Immunology 130, 64–73 (2010).
Abdulahad, W. H. et al. Functional defect of circulating regulatory CD4+ T cells in patients with Wegener’s granulomatosis in remission. Arthritis Rheum. 56, 2080–2091 (2007).
Nogueira, E. et al. Serum IL-17 and IL-23 levels and autoantigen-specific TH17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol. Dial. Transplant. 25, 2209–2217 (2010).
McKinney, E. F. et al. A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat. Med. 16, 586–591 (2010).
Yates, M. et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann. Rheum. Dis. 75, 1583–1594 (2016).
Chen, M., Yu, F., Zhang, Y. & Zhao, M. H. Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine 87, 203–209 (2008).
Katsumata, Y., Kawaguchi, Y. & Yamanaka, H. Interstitial lung disease with ANCA-associated vasculitis. Clin. Med. Insights Circ. Respir. Pulm. Med. 9, 51–56 (2015).
Schönermarck, U., Gross, W. L. & de Groot, K. Treatment of ANCA-associated vasculitis. Nat. Rev. Nephrol. 10, 25–36 (2013).
de Groot, K. et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52, 2461–2469 (2005).
Faurschou, M. et al. Brief report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 3472–3477 (2012).
Jayne, D. R. W. et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 18, 2180–2188 (2007).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00987389 (2018).
Pagnoux, C. et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N. Engl. J. Med. 359, 2790–2803 (2008).
Metzler, C. et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s granulomatosis. Rheumatology 46, 1087–1091 (2007).
Hiemstra, T. F. et al. Mycophenolate mofetil versus azathioprine for remission maintenance in antineutrophil cytoplasmic antibody–associated vasculitis. JAMA 304, 2381 (2010).
Phillip, R. & Luqmani, R. Mortality in systemic vasculitis: a systematic review. Clin. Exp. Rheumatol. 26, S94–S104 (2008).
Tan, J. A. et al. Mortality in ANCA-associated vasculitis: a meta-analysis of observational studies. Ann. Rheum. Dis. 76, 1566–1574 (2017).
Morgan, M. D. et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody–associated vasculitides a matched-pair cohort study. Arthritis Rheum. 60, 3493–3500 (2009).
Lionaki, S. et al. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int. 76, 644–651 (2009).
Sinico, R. A., Di Toma, L. & Radice, A. Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun. Rev. 12, 477–482 (2013).
Bomback, A. S. et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int. 79, 757–764 (2011).
Weiner, M. et al. Outcome and treatment of elderly patients with ANCA-associated vasculitis. Clin. J. Am. Soc. Nephrol. 10, 1128–1135 (2015).
Specks, U. et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N. Engl. J. Med. 369, 417–427 (2013).
Holle, J. U. et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann. Rheum. Dis. 71, 327–333 (2012).
Stevenson, H. C. & Fauci, A. S. Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B cell activation. Immunology 39, 391–397 (1980).
Xiao, H. et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 110, 955–963 (2002).
Specks, U., Fervenza, F. C., McDonald, T. J. & Hogan, M. C. Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. 44, 2836–2840 (2001).
Stasi, R. et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology 45, 1432–1436 (2006).
Keogh, K. A., Wylam, M. E., Stone, J. H. & Specks, U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52, 262–268 (2005).
Keogh, K. A. et al. Rituximab for refractory Wegener’s granulomatosis. Am. J. Respir. Crit. Care Med. 173, 180–187 (2006).
Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2 year results of a randomised trial. Ann. Rheum. Dis. 74, 1178–1182 (2015).
Walsh, M. et al. Risk factors for relapse of antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheum. 64, 542–548 (2012).
Smith, R. M. et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 3760–3769 (2012).
Jones, R. B. et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 60, 2156–2168 (2009).
Cambridge, G. et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 67, 1011–1016 (2008).
Bunch, D. O. et al. Decreased CD5+ B cells in active ANCA vasculitis and relapse after rituximab. Clin. J. Am. Soc. Nephrol. 8, 382–391 (2013).
Guillevin, L. et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N. Engl. J. Med. 371, 1771–1780 (2014).
Terrier, B. et al. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2017-212768 (2018).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01697267 (2018).
Charles, P. et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2017-212878 (2018).
Alberici, F. et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology 54, 1153–1160 (2015).
Molloy, E. S. & Calabrese, L. H. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. 64, 3043–3051 (2012).
Wang, Y. H. et al. Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B cell lymphoma treated with rituximab-containing chemotherapy. Support. Care Cancer 21, 1265–1271 (2013).
Sagnelli, E., Pisaturo, M., Sagnelli, C. & Coppola, N. Rituximab-based treatment, HCV replication, and hepatic flares. Clin. Dev. Immunol. 2012, 1–5 (2012).
Roberts, D. M. et al. Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease. J. Autoimmun. 57, 60–65 (2015).
Roberts, D. M. et al. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. J. Autoimmun. 57, 24–29 (2015).
Venhoff, N. et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS ONE 7, e37626 (2012).
Kaplan, B., Kopyltsova, Y., Khokhar, A., Lam, F. & Bonagura, V. Rituximab and immune deficiency: case series and review of the literature. J. Allergy Clin. Immunol. Pract. 2, 594–600 (2014).
Warnatz, K. et al. B cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc. Natl Acad. Sci. USA 106, 13945–13950 (2009).
Kapetanovic, M. C. et al. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res. Ther. 16, R2 (2014).
Bingham, C. O. et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 62, 64–74 (2010).
Czuczman, M. S. et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 119, 3698–3704 (2012).
Østergaard, M. et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum. 62, 2227–2238 (2010).
McAdoo, S. P. et al. Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series. Rheumatology 55, 1437–1442 (2016).
McAdoo, S. P. et al. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol. Dial. Transplant. 33, 899 (2018).
Bologna, L. et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J. Immunol. 186, 3762–3769 (2011).
Goede, V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370, 1101–1110 (2014).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02550652 (2018).
Ruderman, E. M. & Pope, R. M. The evolving clinical profile of abatacept (CTLA4 Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res. Ther. 7, S21–S25 (2005).
Langford, C. A. et al. An open-label trial of abatacept (CTLA4 Ig) in non-severe relapsing granulomatosis with polyangiitis (Wegener’s). Ann. Rheum. Dis. 73, 1376–1379 (2014).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02108860 (2017).
Walsh, M., Chaudhry, A. & Jayne, D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH 1H). Ann. Rheum. Dis. 67, 1322–1327 (2007).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01405807 (2011).
Mackay, F., Schneider, P., Rennert, P. & Browning, J. BAFF AND APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21, 231–264 (2003).
Rauch, M., Tussiwand, R., Bosco, N. & Rolink, A. G. Crucial role for BAFF-BAFF R signaling in the survival and maintenance of mature B cells. PLoS ONE 4, e5456 (2009).
Schiemann, B. et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293, 2111–2114 (2001).
Sasaki, Y., Casola, S., Kutok, J. L., Rajewsky, K. & Schmidt-Supprian, M. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J. Immunol. 173, 2245–2252 (2004).
Shulga-Morskaya, S. et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J. Immunol. 173, 2331–2341 (2004).
Stadanlick, J. E. et al. Tonic B cell antigen receptor signals supply an NF-κB substrate for prosurvival BLyS signaling. Nat. Immunol. 9, 1379–1387 (2008).
O’Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91–98 (2004).
Xu, S. & Lam, K. P. B cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol. Cell. Biol. 21, 4067–4074 (2001).
Yan, M. et al. Activation and accumulation of B cells in TACI-deficient mice. Nat. Immunol. 2, 638–643 (2001).
Salzer, U. et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat. Genet. 37, 820–828 (2005).
Salzer, U., Jennings, S. & Grimbacher, B. To switch or not to switch — the opposing roles of TACI in terminal B cell differentiation. Eur. J. Immunol. 37, 17–20 (2007).
Thien, M. et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20, 785–798 (2004).
Lesley, R. et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20, 441–453 (2004).
Liu, Z. & Davidson, A. BAFF and selection of autoreactive B cells. Trends Immunol. 32, 388–394 (2011).
Schneeweis, C. et al. Increased levels of BLyS and sVCAM 1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV). Clin. Exp. Rheumatol. 28 (Suppl. 57), 62–66 (2010).
Xin, G. et al. Serum B cell activating factor in myecloperoxiase-antineutrophil cytoplasmic antibodies-associated vasculitis. Am. J. Med. Sci. 348, 25–29 (2014).
Nagai, M. et al. Serum levels of BAFF and APRIL in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis: association with disease activity. Nephron. Clin. Pract. 118, c339–c345 (2011).
Sanders, J. S. F., Huitma, M. G., Kallenberg, C. G. M. & Stegeman, C. A. Plasma levels of soluble interleukin 2 receptor, soluble CD30, IL-10 and BAFF during follow-up in vasculitis associated with proteinase 3 antineutrophil cytoplasmic antibodies: associations with disease activity and relapse. Ann. Rheum. Dis. 65, 1484–1489 (2006).
Bader, L., Koldingsnes, W. & Nossent, J. B lymphocyte activating factor levels are increased in patients with Wegener’s granulomatosis and inversely correlated with ANCA titer. Clin. Rheumatol. 29, 1031–1035 (2010).
De Silva, N. S. & Klein, U. Dynamics of B cells in germinal centres. Nat. Rev. Immunol. 15, 137–148 (2015).
Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M. & Corcoran, L. M. The generation of antibody-secreting plasma cells. Nat. Rev. Immunol. 15, 160–171 (2015).
Vinuesa, C. G., Sanz, I. & Cook, M. C. Dysregulation of germinal centres in autoimmune disease. Nat. Rev. Immunol. 9, 845–857 (2009).
Balázs, M., Martin, F., Zhou, T. & Kearney, J. Blood dendritic cells interact with splenic marginal zone B cells to initiate T independent immune responses. Immunity 17, 341–352 (2002).
Rahman, Z. S., Rao, S. P., Kalled, S. L. & Manser, T. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF R signaling–deficient mice. J. Exp. Med. 198, 1157–1169 (2003).
Gatto, D. & Brink, R. The germinal center reaction. J. Allergy Clin. Immunol. 126, 898–907 (2010).
Kalled, S. L. Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin. Immunol. 18, 290–296 (2006).
Goenka, R. et al. Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation. J. Exp. Med. 211, 45–56 (2014).
Coquery, C. M. et al. BAFF regulates follicular helper T cells and affects their accumulation and interferon γ production in autoimmunity. Arthritis Rheumatol. 67, 773–784 (2015).
Pitzalis, C., Jones, G. W., Bombardieri, M. & Jones, S. A. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat. Rev. Immunol. 14, 447–462 (2014).
Mueller, A., Holl-Ulrich, K., Lamprecht, P. & Gross, W. L. Germinal centre-like structures in Wegener’s granuloma: the morphological basis for autoimmunity? Rheumatology 47, 1111–1113 (2008).
Voswinkel, J., Muller, A. & Lamprecht, P. Is PR3 ANCA formation initiated in Wegener’s granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann. NY Acad. Sci. 1051, 12–19 (2005).
Zhao, Y. et al. Granulomatosis with polyangiitis involves sustained mucosal inflammation that is rich in B cell survival factors and autoantigen. Rheumatology 51, 1580–1586 (2012).
Parsa, R. et al. BAFF-secreting neutrophils drive plasma cell responses during emergency granulopoiesis. J. Exp. Med. 213, 1537–1553 (2016).
Holden, N. J. et al. ANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process. Ann. Rheum. Dis. 70, 2229–2233 (2011).
Bertram, A. et al. Circulating ADAM17 level reflects disease activity in proteinase 3 ANCA-associated vasculitis. J. Am. Soc. Nephrol. 26, 2860–2870 (2015).
Smulski, C. R. et al. BAFF- and TACI-dependent processing of BAFFR by ADAM proteases regulates the survival of B cells. Cell Rep. 18, 2189–2202 (2017).
Kreuzaler, M. et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J. Immunol. 188, 497–503 (2012).
Carter, L. M., Isenberg, D. A. & Ehrenstein, M. R. Elevated serum BAFF levels are associated with rising anti–double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 65, 2672–2679 (2013).
Silverman, G. J. Therapeutic B cell depletion and regeneration in rheumatoid arthritis emerging patterns and paradigms. Arthritis Rheum. 54, 2356–2367 (2006).
Baker, K. P. et al. Generation and characterization of LymphoStat B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48, 3253–3265 (2003).
Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721–731 (2011).
Furie, R. et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918–3930 (2011).
Ginzler, E. M. et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J. Rheumatol. 41, 300–309 (2014).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01639339 (2018).
Stohl, W. et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 64, 2328–2337 (2012).
Halpern, W. G. et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol. Sci. 91, 586–599 (2006).
Lech, M. & Anders, H. J. The pathogenesis of lupus nephritis. J. Am. Soc. Nephrol. 24, 1357–1366 (2013).
Thiel, J. et al. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res. Ther. 19, 101 (2017).
Jayne, D. et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: a multicenter randomized, placebo-controlled study [abstract]. Arthritis Rheumatol. 69 (Suppl. 10), 207AD (2017).
Merrill, J. T. et al. Phase III trial results with blisibimod, a selective inhibitor of B cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 77, 883–889 (2018).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02514967 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01598857 (2015).
Isenberg, D. A. et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE 1, a 52 week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 75, 323–331 (2016).
Schiff, M. et al. Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study. RMD Open 1, e000037 (2015).
Vincent, F. B., Saulep-Easton, D., Figgett, W. A., Fairfax, K. A. & Mackay, F. The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 24, 203–215 (2013).
Ginzler, E. M. et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res. Ther. 14, R33 (2012).
Merrill, J. T. et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus. Arthritis Rheumatol. 70, 266–276 (2018).
Gong, Q. et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174, 817–826 (2005).
Bekar, K. W. et al. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum. 62, 2443–2457 (2010).
Lin, W. et al. Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus. Arthritis Rheumatol. 67, 215–224 (2015).
Kraaij, T. et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J. Autoimmun. 91, 45–54 (2018).
Aranow, C. et al. Phase 2 trial of induction therapy with anti-CD20 (rituximab) followed by maintenance therapy with anti-BAFF (belimumab) in patients with active lupus nephritis [abstract]. Ann. Rheum. Dis. 77, A690 (2018).
BEAT Lupus. BEAT Lupus. BEAT Lupus https://beatlupus.uk/ (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03312907 (2018).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02631538 (2018).
Acknowledgements
The work of the authors is funded by a grant from GlaxoSmithKline (GSK) and the Medical Research Council (MRC) (grant number MR/R502145/1 to D.J. and R.J.). M.M. is in receipt of an MRC–GSK Experimental Medicine Initiative to Explore New Therapies (EMINENT) fellowship and S.G. is funded through the Experimental Medicine Training Initiative.
Reviewer information
Nature Reviews Rheumatology thanks D. Cornec and J. Thiel for their contribution to the peer review of this work.
Author information
Authors and Affiliations
Contributions
M.M. researched data for this article and wrote the manuscript. D.J., M.M. and R.J. made substantial contributions to discussion of content. All authors reviewed and/or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
R.J. and D.J. declare that they have received financial support in the form of a grant from GlaxoSmithKline and the Medical Research Council towards an experimental medicine study evaluating the biological effects of combination therapy with rituximab and belimumab in anti-neutrophil cytoplasmic antibody-associated vasculitis. The other authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
McClure, M., Gopaluni, S., Jayne, D. et al. B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. Nat Rev Rheumatol 14, 580–591 (2018). https://doi.org/10.1038/s41584-018-0065-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-018-0065-x
This article is cited by
-
Update on Cutaneous Small Vessel Vasculitis: Terminology, Morphology, Diagnostic Evaluation, and Management
Current Dermatology Reports (2023)
-
An update on dıagnosıs and treatment of ANCA assocıated renal vasculıtıs
International Urology and Nephrology (2023)
-
Predictors of poor prognosis in ANCA-associated vasculitis (AAV): a single-center prospective study of inpatients in China
Clinical and Experimental Medicine (2022)
-
Novel Therapies for ANCA-associated Vasculitis
Current Rheumatology Reports (2021)
-
Nanoparticle-based approaches to target the lymphatic system for antitumor treatment
Cellular and Molecular Life Sciences (2021)